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ABSTRACT 50 
 51 
Objective Dickkopf-3 (Dkk3) is a non-canonical member of the Dkk family of 52 
Wnt antagonists and its upregulation has been reported in microarray analysis of 53 
cartilage from mouse models of osteoarthritis (OA). In this study we assessed 54 
Dkk3 expression in human OA cartilage  to ascertain its potential role in 55 
chondrocyte signaling and cartilage maintenance. 56 
 57 
Methods Dkk3 expression was analysed in human adult OA cartilage and 58 
synovial tissues and during chondrogenesis of ATDC5 and human mesenchymal 59 
stem cells. The role of Dkk3 in cartilage maintenance was analysed by incubation 60 
of bovine and human cartilage explants with interleukin-1 (IL1) and 61 
oncostatin-M (OSM). Dkk3 expression was measured in cartilage following 62 
murine hip avulsion. Whether Dkk3 influenced Wnt, TGF and activin cell 63 
signaling was assessed in primary human chondrocytes and SW1353 64 
chondrosarcoma cells using RT-qPCR and luminescence assays. 65 
 66 
Results Increased gene and protein levels of Dkk3 were detected in human OA 67 
cartilage, synovial tissue and synovial fluid. DKK3 expression was decreased 68 
during chondrogenesis of both ATDC5 cells and humans MSCs.  Dkk3 inhibited 69 
IL1 and OSM-mediated proteoglycan loss from human and bovine cartilage 70 
explants and collagen loss from bovine cartilage explans. Cartilage DKK3 71 
expression was decreased following hip avulsion injury. TGF signaling was 72 
enhanced by Dkk3 and Wnt3a and activin signaling were inhibited.  73 
 74 
Conclusions We provide evidence that Dkk3 is upregulated in OA and may have 75 
a protective effect on cartilage integrity by preventing proteoglycan loss and 76 
helping to restore OA-relevant signaling pathway activity. Targeting Dkk3 may 77 
be a novel approach in the treatment of OA. 78 
 79 
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INTRODUCTION 99 
 100 
Osteoarthritis (OA) is characterized by loss of articular cartilage, joint pain and 101 
instability.  The mechanisms regulating disease pathogenesis remain elusive 102 
with a combination of genetic, inflammatory, mechanical and metabolic factors 103 
implicated.[1-3]  104 
 105 
Chondrocytes from OA cartilage exhibit a disrupted phenotype, hallmarks of 106 
which include; altered synthesis of extracellular matrix (ECM) and ECM-107 
degrading enzymes, altered cell signaling activity and increased proliferation.[4] 108 
Dysregulation of cell signaling pathways likely contributes to OA pathogenesis by 109 
reducing the chondrocyte’s ability to maintain cartilage integrity, leading to or 110 
exacerbating the phenotypic shift associated with OA. The Wnt and TGF 111 
signaling pathways have been strongly implicated in OA pathogenesis.[5, 6] 112 
 113 
Dickkopf-3 (Dkk3) is a structurally and functionally divergent member of the 114 
Dkk family of Wnt antagonists. Dkk3 activates or inhibits Wnt signaling in a 115 
tissue dependent manner and its impact on cartilage Wnt signaling is 116 
unknown.[7-9] Dkk3 is a tumour suppressor that inhibits proliferation of cancer 117 
cells and is downregulated in several types of human cancer.[8-10] It can 118 
modulate inflammatory cell activity, maintain tissue organisation via TGF 119 
signaling and can protect against myocardial infarction-induced fibrosis.[11-14] 120 
 121 
The function of Dkk3 in other tissues suggests it could be an important mediator 122 
of chondrocyte homeostasis and maintenance of cartilage integrity. Several 123 
studies using animal models of OA have reported increased Dkk3 in diseased 124 
cartilage.[15-17] However Dkk3 expression has not been well characterized in 125 
human OA tissue nor has its role in chondrocyte biology been explored. Our aim 126 
was to assess whether Dkk3 shows aberrant expression in human OA and to 127 
establish whether it can regulate chondrocyte behaviour and OA-associated 128 
cartilage degradation in vitro. 129 
 130 
MATERIALS AND METHODS 131 
 132 
Primary tissue 133 
Primary human OA cartilage and synovium were obtained from age-matched 134 
individuals undergoing hip replacement for OA and control cartilage and 135 
synovium obtained upon hip replacement for neck-of-femur fracture (NOF); 136 
cartilage OA n=13, NOF n=12, OA synovium n=8; NOF synovium n=11. 137 
Anteromedial OA specimens were obtained from patients undergoing 138 
unicompartmental knee replacement for OA. Primary human chondrocytes 139 
(HAC) were obtained from macroscopically normal regions of the tibial plateau 140 
of OA patients undergoing total knee replacement and collagenase digested 141 
following standard protocols. Explants of cartilage were used for proteoglycan 142 
and collagen release assays (DMMB and hydroxyproline respectively). Synovial 143 
fluid was collected from individuals undergoing total knee replacement (TKR, 144 
n=3), unicompartmental knee replacement (UKR, n=3), arthroscopy for cartilage 145 
lesions (n=5), matrix-assisted chondrocyte implantation (MACI, n=7) or control 146 
patients (n=3) with no cartilage lesion but meniscal tears. 147 
 148 
Ethical approval (09/H0606/11 and 2005ORTHO7L) was granted by 149 
Oxfordshire Research Ethics Committee and East Norfolk and Waveney Research  150 
Governance Committee. Informed consent was obtained from all patients 151 
 152 
Cell culture 153 
 154 
SW1353 chondrosarcoma cells (ATCC) and primary HAC were cultured in DMEM 155 
+ 10% (v/v) FCS. ATDC5 cells were cultured in DMEM/F12 (Lonza, UK) 156 
containing 5% (v/v) FCS, 2mM glutamine, 10ug/ml apotransferrin (Sigma) and 157 
30nM sodium selenite. Confluent ATDC5 cells were stimulated to undergo 158 
chondrogenesis by addition of 10ug/ml insulin (Sigma). Human MSCs (Lonza) 159 
were expanded in Mesenchymal Stem Cell Growth Medium (Lonza) 160 
supplemented with 5ng/ml fibroblast growth factor-2 (R&D Systems) before 161 
high density transwell culture as described.[18, 19] Micromass cultures were 162 
established as described [20] before treatment with 100ng/ml Wnt3a for 4 days.  163 
 164 
Cartilage explant assays 165 
Bovine nasal septum and human articular cartilage were dissected and 2mm 166 
cartilage discs explanted and equilibrated for 24 hours before treatment with 167 
IL1 (0.5ng/ml), OSM (5ng/ml) plus Dkk3 (50, 125 and 250ng/ml). Treatments 168 
were refreshed every 2-3 days and collected for GAG and collagen release assays. 169 
Remaining cartilage was harvested at 14 days for papain digestion and DMMB 170 
and hydroxyproline assays.[21] Control and IL1/OSM-treated explants were 171 
collected throughout the time course for RNA extraction (Trizol, Invitrogen, UK), 172 
subsequent cDNA synthesis (Superscript, Invitrogen UK) according to 173 
manufacturer’s instructions prior to RT-qPCR. Three intra-experimental 174 
replicates were carried out for each treatment condition. 175 
 176 
Hip avulsion assay 177 
The hip joint from 5-6 week old C57BL/6J mice was dislocated at the femur and 178 
the femoral cap avulsed using forceps as previously described.[22]  Hip joint 179 
cartilage was cultured for 1-48 hours in serum-free medium before RNA 180 
extraction using Trizol (Invitrogen, UK). cDNA synthesis using Superscript 181 
(Invitrogen, UK) was performed prior to RT-qPCR.  182 
 183 
Immunohistochemistry 184 
Specimens were fixed in 10% (v/v) formalin for 12 hours before decalcification 185 
in 5M HNO3, paraffin embedding and cutting into 5μM sections. Following 186 
deparaffinisation and antigen retrieval with 0.2% (v/v) Triton-X 100, sections 187 
were blocked and incubated at 4C overnight in primary antibody (DKK3, R&D 188 
Systems, Abingdon, UK) before visualisation using Vectastain ABC (Vector 189 
laboratories) with Diaminobenzidine (DAB) and Haematoxylin QS (Vector 190 
laboratories).  191 
 192 
ELISA 193 
Dkk3 level in synovial fluid was measured using Dkk3 ELISA (R&D Systems, UK) 194 
according to manufacturer’s instructions. 195 
 196 
Cytokine treatments 197 
Cells were serum starved overnight and treated with recombinant IL1 (5ng/ml) 198 
and/or OSM(10ng/ml) for 24 hours or pre-treated for 1 hour with recombinant 199 
Dkk3 (250ng/ml unless otherwise stated) or carrier alone (R&D Systems) before 200 
addition of recombinant Wnt3a (100ng/ml,10 hours), activin (20ng/ml, 6 hours) 201 
or TGF1 (4ng/ml, 6 hours) (R&D Systems). Three intra-experimental replicates 202 
were carried out per cytokine treatment. 203 
 204 
Following cytokine treatment cDNA was synthesized using MMLV from DNase-205 
treated cell lysates harvested in Cells-to-cDNA lysis buffer (Ambion) according to 206 
manufacturer’s instructions.   207 
 208 
 209 
RT-qPCR 210 
Expression of genes was measured by RT-qPCR on a ViiA7 (Applied Biosystems).  211 
Relative quantification is expressed as 2−ΔCt, where ΔCt is Ct(gene of interest) – 212 
Ct(18S rRNA). Samples which gave a Ct reading of 18S +1.5Ct greater or less than 213 
the median for 18S were excluded from further analyses. 214 
 215 
Luciferase assays 216 
SW1353 chondrosarcoma cells were used for plasmid transfections using 217 
Lipofectamine 2000 with the Smad-responsive reporter (CAGA)12-luc, Wnt-218 
responsive 8xTCF/LEF binding site (TOPFlash) and mutant TCF/LEF site control 219 
FOPFlash and -galactosidase transfection control plasmid.[23, 24] Cells were 220 
treated with Wnt3a (100ng/ml) for 10 hours or TGF (4ng/ml) or activin 221 
(20ng/ml) for 3 hours with and without 1 hour Dkk3 pre-incubation before 222 
measurement of luciferase activity using the Luciferase and Beta-Glo assay 223 
systems (Promega). 224 
 225 
siRNA 226 
Cells (HAC and SW1353) were transfected with 2.5nM of siRNA against Dkk3 227 
(Qiagen) or  Allstars non-targeting negative control (Qiagen) using Dharmafect 228 
(Thermoscientific, UK) according to manufacturers instructions. Cells were 229 
transfected 48 hours prior to cytokine treatment. 230 
 231 
Statistical analysis 232 
Analyses were carried out using Graphpad Prism 6.0. Students t-test was used to 233 
test differences between two samples whilst ANOVA with either Dunnett’s or 234 
Tukey post-test was used for multiple samples. Normality was tested using the 235 
Shapiro-Wilk test. p<0.05 was considered statistically significant. *0.05, 236 
**0.01, ***0.001. Graphs show mean   95% confidence intervals of biological 237 
(patient or cell) replicates.  238 
 239 
RESULTS 240 
 241 
Dkk3 expression is upregulated in OA tissue 242 
 243 
Expression of DKK3 mRNA was increased >10-fold (p<0.0001) in OA cartilage 244 
compared to NOF control (Figure 1A). Analysis of synovium from OA patients 245 
and NOF controls showed a 3.2-fold (p=0.0235) increase in DKK3 mRNA in 246 
diseased tissue.  DKK3 mRNA expression (Figure 1B) was 2.1-fold (p=0.019) 247 
higher in damaged cartilage from patients with anteromedial OA (AMG). Our 248 
previous work shows reduced MMP and FRZB mRNA expression in damaged 249 
compared to undamaged cartilage.[25] Immunohistochemistry in AMG patients 250 
also showed significant Dkk3 staining in the superficial zone of damaged but not 251 
undamaged cartilage (Figure 1C). Dkk3 protein (Figure 1D) in synovial fluid was 252 
2.1-fold higher (p=0.0002) in patients undergoing total knee replacement for OA 253 
compared to control individuals, those with cartilage lesions (4.33-fold, 254 
p<0.0001) or patients undergoing unicompartmental knee replacement (2.83-255 
fold, p=0.0016). Matrix-induced autologous chondrocyte implantation (MACI) is 256 
performed 4-6 weeks following initial assessment of cartilage lesions by 257 
arthroscopy.  Dkk3 levels at the time of MACI were significantly higher than at 258 
arthroscopy (i.e. lesion) (2.3-fold, p=0.0029). 259 
 260 
DKK3 expression is downregulated following cartilage injury and during 261 
chondrogenesis 262 
 263 
The OA phenotype includes reinitiation of development [26] ,thus establishing 264 
Dkk3 regulation in chondrogenesis is important. ATDC5 differentiation is an 265 
established model of chondrogenesis. Following chondrogenic differentiation, 266 
microarray analysis showed Dkk3 expression decreased relative to non-induced 267 
control cultures (Figure 2A). Expression of chondrogenic markers Col2a1 and 268 
Agc1 (data not shown) were increased across these time points.[23] Human 269 
MSCs in high density transwell cultures also showed a significant 1.3-21-fold 270 
reduction (p<0.01) in DKK3 expression throughout chondrogenic differentiation 271 
into cartilage discs (Figure 2B), with increases in COL2A1 and ACAN across the 272 
time course[18]. 273 
 274 
Joint injury is associated with secondary OA therefore Dkk3 regulation during 275 
injury or in response to inflammatory mediators of injury was investigated. Dkk3 276 
expression in murine cartilage was decreased 1.8-fold (p=0.0005) immediately 277 
(1 hour) following hip avulsion injury and remained low (3.54-fold reduction, 278 
p<0.0001) 48 hours after injury (Figure 2C). Treatment of HAC for 72 hours with 279 
IL1 or the combination IL1/OSM reduced DKK3 expression (2.4-fold, p=0.0086 280 
and 5.25-fold. P=0.0009) (Figure 2D), this was partially inhibited by inhibition of 281 
p38 MAPK activity (Figure 2E). IL1/OSM treatment of HAC induced MMP13 and 282 
MMP1 expression (Figure 2F), this was inhibited by Dkk3 (1.9-fold, p<0.0001 283 
and 3.9-fold, p<0.0001), suggesting Dkk3 inhibits IL1/OSM-induced cartilage 284 
degradation via modulation of MMP levels. 285 
 286 
 287 
Dkk3 prevents cartilage degradation in vitro 288 
 289 
OA is characterized by loss of proteoglycan and collagen from cartilage ECM. 290 
Bovine nasal cartilage (BNC) explants were treated with IL1/OSM +/- 291 
recombinant Dkk3. Cytokine-induced collagen loss (Figure 3A) at day 14 was 292 
dose-dependently inhibited by addition of 50, 125 or 250ng/ml Dkk3 (2.0-, 3.6- 293 
and 5.6-fold reduction p<0.001)  IL1/OSM-induced proteoglycan loss from BNC 294 
explants was also dose-dependently inhibited by 250ng/ml Dkk3 (1.1-fold, 295 
p=0.0049, Figure 3B). Human explants cannot be induced to release collagen 296 
however they showed (Figure 3C) significant dose-dependent inhibition of 297 
cytokine-induced proteoglycan loss in the presence of 125ng/ml and 250ng/ml 298 
Dkk3, (1.6- and 1.5-fold, p=0.003 and p=0.0008, respectively). DKK3 expression 299 
was decreased 1 day after IL1/OSM treatment of BNC explants before increased 300 
expression from day 3 onwards (Figure 3D). No toxicity was detected (LDH 301 
assay) during 14 days treatment with Dkk3 (data not shown). 302 
 303 
Dkk3 inhibits Wnt signaling  304 
 305 
Dkk3 is a non-canonical member of the Dkk family of Wnt antagonists with 306 
tissue-dependent effects on Wnt signaling activity. To determine whether Dkk3 307 
did regulate Wnt signaling in cartilage we treated HAC with Dkk3 and Wnt3a. 308 
The Wnt3a-induced increase of the Wnt target gene AXIN2 (Figure 4A) was 309 
decreased in HAC by co-incubation with Wnt3a and 125, 250 or 500ng/ml Dkk3 310 
(1.6-, 2.2- and 2.5-fold, p=0.0050, <0.0001, <0.0001 respectively) compared to 311 
Wnt3a alone. Furthermore the activity of the Wnt-responsive TOPFlash reporter 312 
was reduced by the addition of Dkk3 (1.7-fold, p=0.0010) (Figure 4B) compared 313 
to Wnt3a alone. Knockdown of Dkk3 in HAC increased Wnt3a-induced AXIN2 314 
expression compared to a non-targeting siRNA control (Figure 4C).  Micromass 315 
cultures of HAC show significant reduction in proteoglycan production following 316 
Wnt3a treatment for 4 days (Figure 4D). Proteoglycan levels were restored by 317 
addition of Dkk3 demonstrating inhibition of Wnt3a-mediated effects on 318 
proteoglycan synthesis.  319 
 320 
Dkk3 regulates TGF signaling  321 
TGF signaling responsiveness is reduced in ageing and OA. Expression of the 322 
TGF-responsive gene, TIMP3,[27] was dose-dependently enhanced in HAC 323 
treated with TGF plus 250 and 500ng/ml Dkk3 compared to TGF alone (2.1- 324 
and 2.2-fold, p<0.001) (Figure 5A). TGF-responsive PAI1 (Supplementary 325 
Figure 2A) and ADAM12 (data not shown) were also enhanced whilst MMP13 326 
expression was decreased by TGF in combination with 250ng/ml Dkk3 (Figure 327 
5C) compared to TGF alone (2.6-fold, p<0.001). 250ng/ml Dkk3 also increased 328 
activity of the TGF-responsive (CAGA)12-luciferase reporter in SW1353 cells 329 
relative to TGF alone (2.8-fold, p<0.0001) (Figure 5B). No effect of Dkk3 alone 330 
was seen on TIMP3, PAI1 or ADAM12 gene expression or CAGA-luc induction. The 331 
extent of TGF induction of TIMP3 (Figure 5D), PAI1 (Supplementary Figure 1B) 332 
and ADAM12 (data not shown) expression and CAGA-luc (Figure 5E) activity was 333 
decreased by Dkk3 knock down. Knockdown of Dkk3 partially repressed the 334 
TGF-induced decrease of MMP13 in primary HAC (Figure 5F). p38 MAPK-335 
mediated stabilization of Smad4 has been described in Xenopus laevis ,[28], 336 
therefore we inhibited p38 MAPK. The induction of TGF-induced TIMP3 (Figure 337 
5G) and PAI1 (Supplementary Figure 2B) expression by Dkk3 was abrogated 338 
following p38 inhibition in HAC (Figure 5G). 339 
 340 
Activin is a member of the TGF superfamily that also signals via Smad2/3. To 341 
assess whether Dkk3 impacted other Smad2/3-related signaling pathways, HAC 342 
and SW1353 were treated with activin +/- Dkk3. Activin induced TIMP3 343 
expression and (CAGA)12-luc activity whilst co-incubation with Dkk3 caused a 344 
dose-dependent reduction in both of these outputs (Figure 6A and 6B). 345 
Knockdown of Dkk3 enhanced activin-induced TIMP3 expression and CAGA-luc 346 
activity suggesting endogenous Dkk3 may act to reduce cellular activin-induced 347 
responses (Figure 6C and 6D). There was no repression of HAC TIMP3 348 
expression when p38 MAPK activity was inhibited (Figure 6E).Activin-induced 349 
PAI1 expression followed the same trends as TIMP3 (Supplementary Figure 3A-350 
C). 351 
 352 
DISCUSSION 353 
Altered expression of cytokines and consequent disruption of cell signaling is 354 
associated with OA pathogenesis. Dkk3 is a non-canonical member of the Dkk 355 
family of Wnt antagonists that has not been explored in cartilage biology despite 356 
numerous studies noting its increased expression in models of OA. In this study 357 
we demonstrate that Dkk3 is upregulated in adult human OA cartilage and 358 
synovial tissue but is decreased during chondrogenesis. Dkk3 protects against in 359 
vitro cartilage degradation and its expression is regulated by both injury and 360 
inflammatory cytokines. Wnt and activin signaling are both inhibited by Dkk3 361 
whilst TGF signaling is enhanced. The upregulation of Dkk3 in OA may be a 362 
protective mechanism to limit cartilage damage and to regulate aberrant cell 363 
signaling associated with disease. 364 
 365 
OA is a complex disease affecting multiple joint tissues, with a unique 366 
combination of factors likely to regulate pathogenesis within each tissue and 367 
across different joint locations. We show that Dkk3 is upregulated in both hip 368 
and knee OA and in both synovial tissue and cartilage from diseased joints. Dkk3 369 
upregulation is also reported in OA subchondral bone from patients undergoing 370 
TKR.[29] This suggests Dkk3 is relevant to whole joint biology in two common 371 
sites of disease. The increased Dkk3 in synovial fluid of patients with 372 
tricompartmental OA may implicate Dkk3 as a biomarker distinguishing end-373 
stage disease. Further studies of Dkk3 as a circulating biomarker are warranted.  374 
 375 
Dysregulation of Wnt and TGF family members has been strongly implicated in 376 
experimental and human OA.[5, 6] An imbalance in Wnt signalling leads to OA 377 
development in murine models, and Wnt antagonists DKK1 and FRZB have been 378 
reported as downregulated in human OA.[30-32] Wnts and activin are also 379 
released following cartilage injury.[33, 34] TGF signaling and responsiveness 380 
decreases with age and OA development whilst increased activin has been 381 
detected in OA tissues .[34, 35] Dkk3 has both agonistic and antagonistic effects 382 
on the Wnt pathway dependent on tissue of expression and thus investigation of 383 
its impact on Wnt signaling in cartilage was investigated in our study.[7-9]. 384 
Opposing regulatory roles of Dkk3 on TGF signaling in Xenopus and prostate 385 
cancer[13, 28] have been reported but its function in musculoskeletal tissue has 386 
not been studied 387 
 388 
In adult HAC we have shown that Dkk3 antagonized Wnt signaling and protected 389 
against Wnt-induced proteoglycan reduction. Dkk3 enhanced TGF signaling in 390 
chondrocytes and interestingly was necessary for TGF-induced reduction of 391 
MMP13 expression. Dkk3 may mediate protective effects on cartilage partially 392 
through upregulation of TGF signaling and inhibition of Wnt signaling. 393 
Surprisingly, Dkk3 inhibited activin signaling in cartilage despite both activin 394 
and TGF commonly signaling through Smad2/3. Inhibition of p38 MAPK 395 
signaling abrogated the effects of Dkk3 on both TGF and activin signaling which 396 
shows Dkk3 action here is p38 MAPK dependent. A previous study demonstrated 397 
Dkk3-dependent Smad4-stabilization by p38 MAPK and this requires further 398 
investigation in chondrocytes.[36] Our data may indicate that Dkk3 effects on 399 
TGF require p38 MAPK for stabilization of Smad4. The effect of Dkk3 on activin 400 
signaling is also p38 MAPK dependent but may operate through a pathway that 401 
does not use Smad 4. The mechanism by which differential regulation of activin 402 
and TGF can occur is currently unknown and beyond the scope of this study. 403 
 404 
Injury to the joint commonly leads to OA development. To model cartilage injury 405 
ex vivo the murine hip was avulsed and Dkk3 levels found to be decreased within 406 
1 hour. Decreased Dkk3 protein was also shown in pilot data from an ex vivo 407 
porcine explant model [37] following cutting injury (data not shown). Treatment 408 
with IL1/OSM also led to a reduction in Dkk3 expression that was partially p38 409 
MAPK dependent. In contrast, previous reports on murine OA[15-17] and our 410 
data in human tissue shows an increase in Dkk3 expression in established 411 
disease. Dkk3 may be regulated in a temporal manner during disease 412 
pathogenesis. This is supported by our BNC data that shows an initial decrease in 413 
DKK3 expression followed by an increase as cartilage degradation occurs.  It is 414 
also of note that synovial fluid Dkk3 levels were lower at the time of arthroscopy 415 
than 4-6 weeks later when MACI was performed. This may indicate that injury to 416 
the joint capsule leads to significant Dkk3 release from other joint tissues that 417 
overcomes any decrease due to cartilage injury.  The sources of Dkk3 in the joint 418 
require further investigation. Any initial injury response leading to decreased 419 
Dkk3 may have been completed at MACI and Dkk3 levels are consequently 420 
increased in the ensuing repair attempt.  421 
 422 
Paralleling the potential roles of the Wnt and TGF pathways in OA pathogenesis, 423 
chondrogenesis and articular cartilage development require TGF signaling as 424 
well as regulation of Wnt signaling.[5, 38] Given the reversion of OA 425 
chondrocytes to a developmental-like phenotype [39] our data showing 426 
decreased Dkk3 during chondrogenesis, shows a potential role for Dkk3 in 427 
chondrogenesis, and also suggests that the immediate downregulation of Dkk3 in 428 
injury may be an early repair response.  429 
 430 
Strikingly, Dkk3 protected against IL1/OSM-stimulated cartilage degradation. 431 
The increase in Dkk3 in OA may be a protective mechanism to minimize cartilage 432 
degradation and the OA-associated shift in chondrocyte phenotype. This is 433 
supported by the reduction in cartilage-degrading MMP13 expression by Dkk3 in 434 
the presence of IL1/OSM. Microarray analysis of HAC treated with siRNA 435 
against Dkk3 did not reveal pathways of Dkk3 action on unstimulated cells (data 436 
not shown), thus future analysis will use cytokine-stimulated. However siRNA 437 
treatment did increase MMP13 expression in TGF-treated cells suggesting that 438 
Dkk3 may limit cartilage damage partially through reduction of both IL1/OSM 439 
and TGF-effects on MMP13. 440 
 441 
Overall Dkk3 upregulation in disease may be a defence mechanism to counteract 442 
disease-related dysregulation of cell signaling pathways; inhibiting inflammatory 443 
cytokine effects on cartilage degradation and enhancing TGF signaling whilst 444 
maintaining regulation of Wnt signaling in an attempt to counteract disease-445 
associated changes in these pathways. Supplementation with Dkk3 at an early 446 
stage of disease or post-injury may therefore be therapeutically beneficial. 447 
 448 
Further investigation of Dkk3 in murine models of OA is necessary to ascertain 449 
its contribution to cartilage homeostasis and disease pathogenesis. Although the 450 
Dkk3 null mouse [40]does not have an overt musculoskeletal phenotype our 451 
preliminary analysis suggests increased knee OA in 3- and 6- month old animals, 452 
we are currently investigating injury-models of OA. Dkk3 gene therapy is in 453 
clinical trial for prostate cancer with promising results,[41] but further 454 
preclinical evaluation is necessary alongside more detailed investigation of the 455 
role of Dkk3 in other tissues of the healthy and OA joint.  456 
 457 
In summary we have demonstrated that Dkk3 is upregulated in human OA and 458 
reduces cartilage degradation. These findings may have clinical implications as 459 
treatment with Dkk3 may prevent cartilage degeneration in OA and early 460 
intervention with Dkk3-based therapy may slow OA progression. 461 
 462 
ACKNOWLEDGEMENTS 463 
We thank Chethan Jayadev and Raj Rout for their assistance in cartilage and 464 
synovial fluid collection, and Fiona Watt and Anastasios Chanalaris for their 465 
assistance with unpublished pilot data on the porcine-injury model. 466 
 467 
CONTRIBUTORS 468 
SJBS and IMC designed the study. SJBS, RKD, TES, MJB, KC and LL carried out data 469 
acquisition. AJC and AP provided patient samples and assisted with data 470 
interpretation. SJBS and IMC carried out data analysis and interpretation. All 471 
authors helped prepared the manuscript and approved the manuscript for 472 
submission.  473 
 474 
FUNDING 475 
Grants: ARUK grants 20087 (SJBS) , 19222 (SJBS), 19424 (MJB) and the NIHR 476 
Oxford Musculoskeletal Biomedical Research Unit funded this work 477 
 478 
COMPETING INTERESTS 479 
The authors have no competing interests to declare. 480 
 481 
REFERENCES 482 
 483 
1. Wojdasiewicz P, Poniatowski LA, Szukiewicz D. The role of inflammatory 484 
and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. 485 
Mediators Inflamm 2014; 2014: 561459. 486 
2. Andriacchi TP, Favre J. The nature of in vivo mechanical signals that 487 
influence cartilage health and progression to knee osteoarthritis. Curr 488 
Rheumatol Rep 2014; 16: 463. 489 
3. Loeser RF. Aging processes and the development of osteoarthritis. Curr 490 
Opin Rheumatol 2013; 25: 108-113. 491 
4. Goldring MB. The role of the chondrocyte in osteoarthritis. Arthritis 492 
Rheum 2000; 43: 1916-1926. 493 
5. Staines KA, Macrae VE, Farquharson C. Cartilage development and 494 
degeneration: a Wnt Wnt situation. Cell Biochem Funct 2012; 30: 633-495 
642. 496 
6. van der Kraan PM, Goumans MJ, Blaney Davidson E, ten Dijke P. Age-497 
dependent alteration of TGF-beta signalling in osteoarthritis. Cell Tissue 498 
Res 2012; 347: 257-265. 499 
7. Nakamura RE, Hunter DD, Yi H, Brunken WJ, Hackam AS. Identification of 500 
two novel activities of the Wnt signaling regulator Dickkopf 3 and 501 
characterization of its expression in the mouse retina. BMC Cell Biol 2007; 502 
8: 52. 503 
8. Ueno K, Hirata H, Majid S, Chen Y, Zaman MS, Tabatabai ZL, et al. Wnt 504 
antagonist DICKKOPF-3 (Dkk-3) induces apoptosis in human renal cell 505 
carcinoma. Mol Carcinog 2011; 50: 449-457. 506 
9. Yue W, Sun Q, Dacic S, Landreneau RJ, Siegfried JM, Yu J, et al. 507 
Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung 508 
cancer. Carcinogenesis 2008; 29: 84-92. 509 
10. Wang Z, Ma LJ, Kang Y, Li X, Zhang XJ. Dickkopf-3 (Dkk3) induces 510 
apoptosis in cisplatin-resistant lung adenocarcinoma cells via the 511 
Wnt/beta-catenin pathway. Oncol Rep 2015; 33: 1097-1106. 512 
11. Kinoshita R, Watanabe M, Huang P, Li SA, Sakaguchi M, Kumon H, et al. 513 
The cysteine-rich core domain of REIC/Dkk-3 is critical for its effect on 514 
monocyte differentiation and tumor regression. Oncol Rep 2015; 33: 515 
2908-2914. 516 
12. Meister M, Papatriantafyllou M, Nordstrom V, Kumar V, Ludwig J, Lui KO, 517 
et al. Dickkopf-3, a tissue-derived modulator of local T-cell responses. 518 
Front Immunol 2015; 6: 78. 519 
13. Romero D, Kawano Y, Bengoa N, Walker MM, Maltry N, Niehrs C, et al. 520 
Downregulation of Dickkopf-3 disrupts prostate acinar morphogenesis 521 
through TGF-beta/Smad signalling. J Cell Sci 2013; 126: 1858-1867. 522 
14. Zhang Y, Liu Y, Zhu XH, Zhang XD, Jiang DS, Bian ZY, et al. Dickkopf-3 523 
attenuates pressure overload-induced cardiac remodelling. Cardiovasc 524 
Res 2014; 102: 35-45. 525 
15. Blom AB, Brockbank SM, van Lent PL, van Beuningen HM, Geurts J, 526 
Takahashi N, et al. Involvement of the Wnt signaling pathway in 527 
experimental and human osteoarthritis: prominent role of Wnt-induced 528 
signaling protein 1. Arthritis Rheum 2009; 60: 501-512. 529 
16. Meng J, Ma X, Ma D, Xu C. Microarray analysis of differential gene 530 
expression in temporomandibular joint condylar cartilage after 531 
experimentally induced osteoarthritis. Osteoarthritis Cartilage 2005; 13: 532 
1115-1125. 533 
17. Loeser RF, Olex AL, McNulty MA, Carlson CS, Callahan MF, Ferguson CM, et 534 
al. Microarray analysis reveals age-related differences in gene expression 535 
during the development of osteoarthritis in mice. Arthritis Rheum 2012; 536 
64: 705-717. 537 
18. M J. Barter M, R Gómez, S Woods, W Hui, G R. Smith, D P. Shanley, I M. 538 
Clark, D A. Young. Genome-wide microRNA and gene analysis of 539 
mesenchymal stem cell chondrogenesis identifies an essential role and 540 
multiple targets for miR-140-5p. Stem Cells 2015. 541 
19. Murdoch AD, Grady LM, Ablett MP, Katopodi T, Meadows RS, Hardingham 542 
TE. Chondrogenic differentiation of human bone marrow stem cells in 543 
transwell cultures: generation of scaffold-free cartilage. Stem Cells 2007; 544 
25: 2786-2796. 545 
20. Greco KV, Iqbal AJ, Rattazzi L, Nalesso G, Moradi-Bidhendi N, Moore AR, et 546 
al. High density micromass cultures of a human chondrocyte cell line: a 547 
reliable assay system to reveal the modulatory functions of 548 
pharmacological agents. Biochem Pharmacol 2011; 82: 1919-1929. 549 
21. Davidson RK, Jupp O, de Ferrars R, Kay CD, Culley KL, Norton R, et al. 550 
Sulforaphane represses matrix-degrading proteases and protects 551 
cartilage from destruction in vitro and in vivo. Arthritis Rheum 2013; 65: 552 
3130-3140. 553 
22. Chong KW, Chanalaris A, Burleigh A, Jin H, Watt FE, Saklatvala J, et al. 554 
Fibroblast growth factor 2 drives changes in gene expression following 555 
injury to murine cartilage in vitro and in vivo. Arthritis Rheum 2013; 65: 556 
2346-2355. 557 
23. Swingler TE, Wheeler G, Carmont V, Elliott HR, Barter MJ, Abu-Elmagd M, 558 
et al. The expression and function of microRNAs in chondrogenesis and 559 
osteoarthritis. Arthritis Rheum 2012; 64: 1909-1919. 560 
24. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, et 561 
al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in 562 
APC-/- colon carcinoma. Science 1997; 275: 1784-1787. 563 
25. Snelling S, Rout R, Davidson R, Clark I, Carr A, Hulley PA, et al. A gene 564 
expression study of normal and damaged cartilage in anteromedial 565 
gonarthrosis, a phenotype of osteoarthritis. Osteoarthritis Cartilage 2014; 566 
22: 334-343. 567 
26. Saito T, Kawaguchi H. HIF-2alpha as a possible therapeutic target of 568 
osteoarthritis. Osteoarthritis Cartilage 2010; 18: 1552-1556. 569 
27. Su S, Dehnade F, Zafarullah M. Regulation of tissue inhibitor of 570 
metalloproteinases-3 gene expression by transforming growth factor-beta 571 
and dexamethasone in bovine and human articular chondrocytes. DNA 572 
Cell Biol 1996; 15: 1039-1048. 573 
28. Pinho S, Niehrs C. Dkk3 is required for TGF-beta signaling during Xenopus 574 
mesoderm induction. Differentiation 2007; 75: 957-967. 575 
29. Chou CH, Lee CH, Lu LS, Song IW, Chuang HP, Kuo SY, et al. Direct 576 
assessment of articular cartilage and underlying subchondral bone 577 
reveals a progressive gene expression change in human osteoarthritic 578 
knees. Osteoarthritis Cartilage 2013; 21: 450-461. 579 
30. Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, et al. Activation of beta-catenin 580 
signaling in articular chondrocytes leads to osteoarthritis-like phenotype 581 
in adult beta-catenin conditional activation mice. J Bone Miner Res 2009; 582 
24: 12-21. 583 
31. Zhu M, Chen M, Zuscik M, Wu Q, Wang YJ, Rosier RN, et al. Inhibition of 584 
beta-catenin signaling in articular chondrocytes results in articular 585 
cartilage destruction. Arthritis Rheum 2008; 58: 2053-2064. 586 
32. Leijten JC, Bos SD, Landman EB, Georgi N, Jahr H, Meulenbelt I, et al. 587 
GREM1, FRZB and DKK1 mRNA levels correlate with osteoarthritis and 588 
are regulated by osteoarthritis-associated factors. Arthritis Res Ther 589 
2013; 15: R126. 590 
33. Dell'accio F, De Bari C, Eltawil NM, Vanhummelen P, Pitzalis C. 591 
Identification of the molecular response of articular cartilage to injury, by 592 
microarray screening: Wnt-16 expression and signaling after injury and in 593 
osteoarthritis. Arthritis Rheum 2008; 58: 1410-1421. 594 
34. Alexander S, Watt F, Sawaji Y, Hermansson M, Saklatvala J. Activin A is an 595 
anticatabolic autocrine cytokine in articular cartilage whose production is 596 
controlled by fibroblast growth factor 2 and NF-kappaB. Arthritis Rheum 597 
2007; 56: 3715-3725. 598 
35. van der Kraan PM. Age-related alterations in TGF beta signaling as a 599 
causal factor of cartilage degeneration in osteoarthritis. Biomed Mater 600 
Eng 2014; 24: 75-80. 601 
36. Hsu RJ, Lin CC, Su YF, Tsai HJ. dickkopf-3-related gene regulates the 602 
expression of zebrafish myf5 gene through phosphorylated p38a-603 
dependent Smad4 activity. J Biol Chem 2011; 286: 6855-6864. 604 
37. Gruber J, Vincent TL, Hermansson M, Bolton M, Wait R, Saklatvala J. 605 
Induction of interleukin-1 in articular cartilage by explantation and 606 
cutting. Arthritis Rheum 2004; 50: 2539-2546. 607 
38. Shen J, Li S, Chen D. TGF-beta signaling and the development of 608 
osteoarthritis. Bone Res 2014; 2. 609 
39. van der Kraan PM, van den Berg WB. Chondrocyte hypertrophy and 610 
osteoarthritis: role in initiation and progression of cartilage 611 
degeneration? Osteoarthritis Cartilage 2012; 20: 223-232. 612 
40. Barrantes Idel B, Montero-Pedrazuela A, Guadano-Ferraz A, Obregon MJ, 613 
Martinez de Mena R, Gailus-Durner V, et al. Generation and 614 
characterization of dickkopf3 mutant mice. Mol Cell Biol 2006; 26: 2317-615 
2326. 616 
41. Kumon H, Sasaki K, Ariyoshi Y, Sadahira T, Ebara S, Hiraki T, et al. Ad-617 
REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC 618 
Following Chemotherapy. Clin Med Insights Oncol 2015; 9: 31-38. 619 
 620 
 621 
 622 
  623 
 624 
 625 
 626 
 627 
 628 
 629 
 630 
 631 
 632 
 633 
 634 
 635 
FIGURE LEGENDS 636 
 637 
Figure 1. Dkk3 levels are altered in OA and during chondrogenesis  638 
 639 
(A) DKK3 expression is elevated in OA cartilage and synovium from patients 640 
undergoing total hip arthroplasty. OA cartilage = COA, n=13 NOF control 641 
cartilage (CN, n=11) OA synovium (SOA, n=8) and NOF control synovium (SN, 642 
n=11). DKK3 gene (B) and protein (C) levels were elevated in damaged compared 643 
to undamaged cartilage from individuals with AMG (n=5), IHC scale bar = 20M. 644 
(D) Dkk3 protein measured by ELISA of synovial fluid was increased in 645 
individuals undergoing TKR for OA, n=3. Levels were also measured in 646 
individuals with no cartilage lesions (control, n=3), undergoing arthroplasty for 647 
cartilage lesions (lesion, n=5), matrix-induced autologous chondrocyte 648 
implantation (MACI, n=7) following arthroscopy, or uni- compartmental (UKR, 649 
n=3) knee replacement for AMG. (A, B) analysed by t-test, (D) by ANOVA with 650 
Tukey post-test, three technical replicates per patient with the mean of these 651 
used in statistical analysis and represented as a dot (biological replicate) on each 652 
graph.. 653 
 654 
Figure 2. Dkk3 is regulated by inflammatory cytokines and injury and 655 
during chondrogenesis 656 
(A) qRT-PCR of RNA extracted from murine hip cartilage following ex vivo 657 
avulsion showed a reduction in DKK3 expression (n=8 mice). (B) 24 hour 658 
treatment with IL1 and IL1/OSM reduced DKK3 expression in primary 659 
monolayer HAC (n=4 patients, 4 technical replicates per condition), this was 660 
partially inhibited by 10M of the p38 MAPK inhibitor SB202190 (SB) (n=4 661 
patients, 4 technical replicates per condition) (C).  (D) IL1/OSM-induced MMP13 662 
and MMP1 expression was inhibited by Dkk3 (n=4 patients, 4 technical replicates 663 
per condition). DKK3 expression was reduced during chondrogenesis of ATDC5 664 
cells (microarray) and human MSCs (RT-qPCR, n=2-3 biological replicates)(E & 665 
F).  (A-D) and (F) ANOVA with Dunnett’s post-test. All statistical analysis carried 666 
out on biological replicates. 667 
 668 
 669 
Figure 3. Dkk3 inhibits ex vivo cartilage degradation. 670 
 671 
(A)Dkk3 reduced IL1/OSM-induced collagen degradation (hydroxyproline 672 
release) from bovine nasal cartilage (BNC) explants (n=4 biological replicates, 3 673 
technical replicates per condition). (B) BNC (n=4) and (C) human knee (n=4) 674 
cartilage explants showed a reduction in proteoglycan degradation (GAG release, 675 
DMMB assay) in the presence of Dkk3 compared to IL1/OSM treatment alone, 3 676 
technical replicates per condition. DKK3 expression was significantly reduced in 677 
BNC (n=3) at day 1 of IL1/OSM treatment and increased from day 5 onwards.  678 
(A), (B) and (C) ANOVA with Dunnett’s post-test relative to IL1/OSM alone (D) t-679 
test relative to untreated timepoint control. I/O = IL1/OSM. All statistical 680 
analysis carried out on biological replicates (each biological replicate the mean of 681 
technical replicates for that sample). 682 
 683 
 684 
Figure 4. Dkk3 inhibits Wnt signaling in chondrocytes. 685 
(A) HAC (n=4 patients, 3 technical replicates per condition) were treated with 686 
Wnt3a with 0-500ng/ml Dkk3 and AXIN2 expression was reduced in the 687 
presence of Dkk3.  (B) SW1353 cells were transfected with the TOPFlash 688 
reporter plasmid and FOPFlash control. Luminescence was assessed following 689 
treatment with Wnt3a, Dkk3 or the combination of Wnt3a and Dkk3. Dkk3 690 
reduced Wnt3a-induced luciferase activity (n=8). (C) Dkk3 inhibited the Wnt3a-691 
induced reduction in proteoglycan production of HAC grown in micromass 692 
culture (n=4) as measured by alcian blue staining, meanSD. (D) Primary HAC 693 
(n=4) were treated with siRNA against Dkk3 or negative control siRNA. In the 694 
absence of Dkk3 there was a relative increase in Wnt3a-induced AXIN2 695 
expression. ANOVA with Dunnett’s post-test, (A,B, D) significance shown for 696 
comparisons of Wnt3a to Wnt3a + Dkk3, (C) significance shown for comparisons 697 
of Wnt3a_siRNAcontrol to Wnt3siRNADkk3. n represents biological replicates 698 
(the mean of 3 technical replicates per condition for luciferase assays and 4 699 
technical replicates per condition for gene expression assays). All statistical 700 
analysis carried out on biological replicates. 701 
 702 
Figure 5. Dkk3 enhances TGFβ signaling response. 703 
(A) HAC (n=4) treated with TGF showed increased TIMP3 expression in the 704 
presence Dkk3 compared to TGF alone. (B) TGF-responsive (CAGA)12-705 
luciferase activity in SW1353 cells (n=8) was also enhanced by Dkk3 compared 706 
to TGF alone. TGF-induced TIMP3 expression (C, n=4) and (CAGA)12-luciferase 707 
activity (D, n=8) was reduced following knockdown of Dkk3. (E) Inhibition of 708 
HAC p38 MAPK activity by treatment with 10M SB202190 (SB) abolished the 709 
Dkk3-induced enhancement of TIMP3 expression following TGF treatment 710 
(n=3). (F) Dkk3 treatment decreased MMP13 expression in HAC compared to 711 
TGF treatment alone (n=4) and siRNA against Dkk3 partially inhibited the 712 
TGF-induced reduction in MMP13 expression in HAC (n=4) (G). (A-F)ANOVA 713 
with Dunnett’s post-test, significance shown for comparison between TGF alone 714 
and TGF + Dkk3 (A-C) and for TGF + siControl to TGF+ siDkk3 (D-F). (G) 715 
ANOVA plus Tukey post-test, significance shown for comparison of TGF + Dkk3 716 
to TGF alone for with and without SB202190. n represents biological replicates 717 
(the mean of 3 technical replicates per condition for luciferase assays and 4 718 
technical replicates per condition for gene expression assays). All statistical 719 
analysis carried out on biological replicates. 720 
 721 
 722 
Figure 6. Dkk3 inhibits activin signaling response 723 
(A) HAC (n=4) treated with activin showed increased TIMP3 expression in the 724 
presence Dkk3 compard to Activin alone. (B) (CAGA)12-luciferase activity in 725 
SW1353 cells (n=8) was also reduced in the presence of Dkk3 compared to 726 
activin alone. Activin-induced TIMP3 expression (C, n=4) and (CAGA)12-luciferase 727 
activity (D, n=4) was increased following knockdown of Dkk3. (E) Inhibition of 728 
HAC p38 MAPK activity by treatment with 10M SB202190 (SB) abolished the 729 
Dkk3 (250ng/ml)-induced reduction in TIMP3 expression following Activin 730 
treatment (n=4). (A-D) ANOVA with Dunnett’s post-test, significance shown for 731 
comparison between Activin and Activin + Dkk3 (A, B) and between 732 
Activin_siControl and Activin_siDkk3 (C,D). (E) ANOVA with Tukey post-test, 733 
significance shown for comparison between Activin alone and Activin + Dkk3 in 734 
the absence and presence of SB202190. n represents biological replicates (the 735 
mean of 3 technical replicates per condition for luciferase assays and 4 technical 736 
replicates per condition for gene expression assays). All statistical analysis 737 
carried out on biological replicates. 738 
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